10 x '20 Progress--Development of New Drugs Active Against Gram-Negative Bacilli: An Update From the Infectious Diseases Society of America

Infections caused by antibiotic-resistant bacteria, especially the "ESKAPE" pathogens, continue to increase in frequency and cause significant morbidity and mortality. New antimicrobial agents are greatly needed to treat infections caused by gram-negative bacilli (GNB) resistant to currently available agents. The Infectious Diseases Society of America (IDSA) continues to propose legislative, regulatory, and funding solutions to this continuing crisis. The current report updates the status of development and approval of systemic antibiotics in the United States as of early 2013. Only 2 new antibiotics have been approved since IDSA's 2009 pipeline status report, and the number of new antibiotics annually…

• UD
  U.S. Department of Veterans Affairs
• P
  Pfizer
• AP
  Astellas Pharma US
• A
  AstraZeneca
• G
  GlaxoSmithKline
• S
  Sanofi
• ID
  Infectious Diseases Society of America
• EF
  European Food Safety Authority
• NT
  Nabriva Therapeutics
• BH
  Bayer HealthCare
• AP
  Astellas Pharma
• S
  Shionogi
• NI
  National Institutes of Health

  Awards: 1K24HD058735-01, R01AI072219 and R01AI063517, 1R01HD057956-02, HHSN267200700051C, 1R01FD003519-01, R01AI072219, R01AI063517, 1U10-HD45962-06
• UO
  University of California, San Diego
• GR
  Geriatric Research Education and Clinical Center

  Award: VISN 10
• NC
  NIH Clinical Center
• UP
  UCB Pharma